

# Neurotech

## Quarterly report for the period ending 31 December 2016

- *IPO & ASX listing – A\$7m capital raised*
- *Mente Autism receives CE approval, product launched with first batches delivered to Italian distributor on schedule*
  - *Key appointment of Chief Commercial Officer Mario Raciti*
  - *Appointment of high calibre Scientific Advisory Board*
- *Advanced negotiations with potential new partners & distributors*
  - *ISO 13485 audit passed*

**Perth, Australia & Malta – 31 January 2017** – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) is pleased to present its quarterly report for the period ending 31 December 2016.

Neurotech’s focus during the quarter was progressing the commercial launch of its flagship product, *Mente Autism*, following the Company’s successful IPO in November 2016 which raised A\$7 million for the Company.

*Mente Autism* was launched in November following the receipt of CE Marking for the product earlier in the quarter, certifying that it complies with European health, safety and environmental protection legislation.

The third iteration of the device, *Mente Autism* provides improved accuracy, a higher quality therapy and greater freedom of movement to the user. Under its key distribution agreement Neurotech shipped and invoiced the first 30 units to Italy in late December. This month a further 28 *Mente Autism* devices have been shipped to other distributors in Europe, Africa and East Asia.

The Company appointed Chief Commercial Officer Mario Raciti during the period, providing commercial expertise and go-to-market industry knowledge. Mario is based in Germany, a key target market for *Mente Autism*, and is tasked with leading the Company’s market development throughout Europe.

A Scientific Advisory Board, comprising leading experts and medical professionals, was also appointed in December to help guide the Company’s substantial ongoing Research and Development investment. The members of the board are:

- Prof Paolo Cavallari – University of Milan
- Prof Denis Azzopardi – Kings College, UK
- Dr David. S. Cantor – Former President of the EEG and Clinical Neuroscience Society, USA
- Dr Anton Grech – Senior Research Fellow at the Bedfordshire Centre for Mental Health Research in association with University of Cambridge

The first meeting of the Scientific Advisory Board was held subsequent to the end of the quarter.

Neurotech’s subsidiary, AAT Medical, passed the ISO 13485 audit during the period. The audit provides certification that the Company has the correct infrastructure and quality control to develop and

---

### Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

[www.neurotechinternational.com](http://www.neurotechinternational.com)

manufacture medical devices. Passing this annual audit is a pre-requisite for maintaining Mente Autism's CE mark registration.

### **Progress on key priorities**

Neurotech continued to consolidate its brand architecture for Mente Autism and the Mente product family. This brand architecture provides the Company with a consistent yet flexible image that will facilitate the inclusion of future products. These products will be added under the Mente umbrella brand. As part of this brand consolidation, the Company launched a revamped website, a new Mente Autism video, promotional materials and updated logos.

In supporting the launch of Mente Autism, Neurotech management also conducted several visits to Italy targeting the key areas of Puglia and Campania. These visits enabled the management team to meet with key opinion leaders and regional authorities in the region and provide training and educational sessions.

The Company made continued progress on the future product pipeline for the B2B market, with the development of Mente Pro and Mente Suite on track.

Earlier in the quarter, Neurotech also took part in one of the largest medical fairs in the world, Medica. Held in Dusseldorf, Germany, Medica was an important event at which management met with numerous potential distributors and potential partners. Consistent with its focus on marketing efforts, Neurotech will attend several other conventions, conferences and trade shows in 2017 to promote awareness of the Company and its flagship product, Mente Autism.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

-ends-

### **About Neurotech**

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: <http://www.neurotechinternational.com>.

*For more information please contact:*

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Tel: +61 451 896 420